Zydus Lifesciences Pioneers India's First Biosimilar for Eye Care
Zydus Lifesciences has launched Anyra, India's first indigenously developed biosimilar for visual impairment, derived from Aflibercept 2 mg. The move aims to enhance ophthalmic care and expand access to affordable biologics for the country's large diabetic population.
- Country:
- India
Zydus Lifesciences unveiled Anyra, marking the country's initial venture into indigenously developed biosimilars for treating visual impairment. The drug, based on Aflibercept 2 mg, targets various conditions, including diabetes-induced vision issues.
The launch strengthens the company’s commitment to improving ophthalmic care, providing high-quality, cost-effective biologics to patients across India. With over 100 million diabetics in India, this development represents a significant step in accessible healthcare solutions.
Additionally, Zydus reached an agreement with Regeneron Pharmaceuticals and Bayer for Anyra. Meanwhile, the company's shares experienced a slight rise, trading at Rs 910.25 each on the BSE.
Advertisement
Google News